Brief Program Overview/Description:
The Pathophysiological and Therapeutic Markers RFP Grant Round 2024 aims to advance the understanding of pathophysiology and the utilization of biological markers in hypermobility spectrum disorders (HSD) and the Ehlers-Danlos syndromes (EDS). This initiative seeks to address critical issues by encouraging multidisciplinary teams to investigate specific patient populations and underlying biological mechanisms, fostering collaboration for the benefit of affected communities. Clear criteria and study designs are vital for this research round.
Minimum Requirements and Eligibility:
The Ehlers-Danlos Society invites research proposals to advance the understanding of pathophysiology and the utilization of biological markers in HSD and EDS. Recognizing the novelty of areas such as epigenomics, transcriptomics, proteomics, metabolomics, and tissue histology in HSD and EDS research, the commitment is to provide sustained annual support across the translational pathway, fostering bidirectional collaboration between basic and clinical research.
In line with research priorities, the key areas of interest and criteria for applications include:
- The identification of diagnostic or susceptibility biomarkers to detect or confirm the presence of HSD or hypermobile EDS (hEDS) or indicate the potential for developing either of these or any of their comorbidities.
- The identification of pathophysiological markers that demonstrate potential pathways for therapeutic interventions in any type of EDS or HSD.
- The exploration of existing markers in any type of EDS or HSD for their potential in monitoring therapeutic interventions, including predictive, responsive, and safety/monitoring markers, to identify individuals more likely than similar individuals without the biomarker to experience a favorable or unfavorable effect from exposure to a medical product or an environmental agent.
- Prognostic biomarkers that identify the likelihood of a clinical event or disease progression in HSD or EDS.
Research proposals should demonstrate meeting one or more of the above criteria. Studies involving biomarkers such as imaging characteristics and not primarily addressing the field of epigenetics, transcriptomics, proteomics, metabolomics or histology will not be considered in this RFP. Researchers unsure as to whether their study will meet the criteria should contact The Ehlers-Danlos Society at [email protected] before submitting an application.
There are considerable benefits to using biomarkers to study various aspects of disease processes in HSD and EDS, improving diagnostic and decision-making processes, and facilitating the development and monitoring of therapies. Toward this effort, The Ehlers-Danlos Society has also established a Global Biobank to support research opportunities. The Biobank and this research grant round is made possible thanks to an incredible $6.7 million donation to research made in December 2023 by the Mike and Sofia Segal Foundation.
The aim of the Global Biobank is to build a repository of phenotype data and tissue samples for use by researchers internationally. The Ehlers-Danlos Society seeks to provide clinical data and biological samples to expedite and support research projects in future grant rounds. The Ehlers-Danlos Society will collaborate with successful applicants to this RFP round, where possible, in gathering and storing data and tissue samples within the biobank. The ability of an applicant to collaborate in this way is desirable but not essential and will not influence success in the grant round.
Key Dates:
- Research Funding Announcement: May 20th, 2024
- Full Application Deadline: July 20th, 2024
- Notification to Applicants: Week of September 30th , 2024
Funding Amounts (IDC 5%):
We have allocated a total of $900,000 with the goal of funding 3-4 studies. Each grant is intended to cover expenses up to $300,000. The Indirect Cost percentage allowed for this study is 5%.